Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Myeloma Stage 1- R,V,D Induction, I.V. Vit. C, Over-Diagnosis?
Myeloma Stage 1- R,V,D Induction, I.V. Vit. C, Over-Diagnosis?
Intravenous vitamin C (ascorbic acid and L-ascorbic acid) therapy is the ideal integrative, complementary, non-toxic, evidence-based therapy for multiple myeloma patients and survivors.
Greetings David! Thank you so very very much for the tremendous amount of information that you provide on PeopleBeatingCancer.org. I so wish I had the resources to do MM cancer coaching with you and dearly appreciate your being available to answer questions.
I read about IV Vitamin C therapy for MM and have located a place to be able to do that.
I am about 5 weeks in my first cycle of induction chemotherapy of revlimid, velcade and dexamethasone (RVD). I started on Dex though had a rough reaction to it and was taken off of it.
- No M-spike detected nor
- kidney damage thus far and very grateful.
- 30% detected with a BMB.
- I am IGg kappa.
I was also informed about oxygen therapy in a hyperberic chamber (HBOT) located at a clinic nearby. Is that something you would recommend as well as the I.V. Vitamin C infusion? Thank you so very much for your perspective and taking the time to answer me. Liz
Hi Liz,
Thank you for the kind words. I am sorry to read of your MM diagnosis. If I understand your comments, with
- no m-spike,
- 30% mm cells in your blood (BMB) and
- no kidney involvement
- IgG Kappa,
you have pre-MM, or at the very most early, early stage multiple myeloma. Please reference the Salmon-Durie classification criteria linked below.
My personal belief is that it is common for conventional oncology to over-diagnose and therefore over-treat cancer patients in general and MM patients specifically. Are you working with a general oncologist or a MM specialist?
You are an excellent candidate for evidence-based, not-toxic therapies such as:
- intravenous vitamin C therapy,
- anti-angiogenic nutrition and supplementation such as curcumin and omega-3 fatty acids,
- frequent, moderate exercise
- lifestyle therapies
as well as the other evidence-based, non-toxic, anti-MM therapies listed in the MM CC program. I say this because the non-toxic therapies in the MM CC program are more effective when the MM patient is in complete remission or, as in your case, the MM is at an early stage.
Yes, I have undergone hyperbaric oxygen therapy (HBOT). The studies about it’s anti-cancer efficacy are limited but there is reason to believe that oxygen combats cancer, especially systemic cancer circulating in our blood stream. HBOT provides many health benefits in addition to being anti-cancer.
Regarding your current conventional induction therapy of RVd, it is common to have a reaction to either/or dex, rev., etc. With your MM being as such an early stage, please consider stoping therapy when you reach complete remission. CR may be reached, for example, in 3 rounds/courses of therapy, before the usual or standard six rounds. Less chemo is less toxicity, less organ damage. Your oncologist may want you to undergo all six.
The point is that once you reach complete remission, according to research, more chemotherapy will not result in longer overall survival, just more organ damage. Further, the more chemo you undergo the faster you will become resistant aka MDR. You can ask your oncologist about these issues. If your MM does not become resistant to either revlimid or velcade, then you can take integrative therapies such as curcumin or omega-3’s shown to enhance the efficacy of these chemotherapy regimens.
Lastly, one of the most important aspects of the MM CC program is having an ongoing resource of full-spectrum, evidence-based therapies to undergo after your conventional therapies. I believe that conventional oncology doesn’t stress the importance of anti-MM therapy AFTER conventional therapies in order to deepen and lengthen remission.
- To Learn More about intravenous vitamin C therapy and Myeloma- click now
- To Learn More about Newly Diagnosed Multiple Myeloma Stage 1- click now
I’ve tried to cover a bunch of different issues in responding to your question. Let me know if you have any other questions.
thanks and hang in there,
David Emerson
- MM Survivor
- MM Coach
- Director PeopleBeatingCancer
Recommended Reading:
What is the Salmon-Durie classification of multiple myeloma (MM)?
In stage I, the MM cell mass is less than 0.6 × 1012 cells/m2, and all of the following are present:
-
Hemoglobin value >10 g/dL
-
Serum calcium value < 12 mg/dL (normal)
-
Normal bone structure (scale 0) or only a solitary bone plasmacytoma on radiographs
-
Low M-component production rates (IgG value < 5 g/dL, IgA value < 3 g/dL, urine light-chain M component on electrophoresis < 4 g/24 h)
In stage II, the MM cell mass is 0.6-1.2 × 1012 cells/m2 or more. The other values fit neither those of stage I nor those of stage III.
In stage III, the MM cell mass is >1.2 × 1012 cells/m2, and all of the following are present:
-
Hemoglobin value < 8.5 g/dL
-
Serum calcium value >12 mg/dL
-
Advanced lytic bone lesions (scale 3) on radiographs
-
High M-component production rates (IgG value greater than 7 g/dL, IgA value greater than 5 g/dL, urine light-chain M component on electrophoresis greater than 12 g/24 h)
Subclassification A includes relatively normal renal function (serum creatinine value < 2 mg/dL), whereas subclassification B includes abnormal renal function (serum creatinine value > 2 mg/dL)
Median survival is as follows:
-
Stage I, >60 months
-
Stage II, 41 months
-
Stage III, 23 months
Multiple Myeloma- Intravenous Vitamin C Therapy
Intravenous vitamin C (ascorbic acid and L-ascorbic acid) therapy is the ideal integrative, complementary, non-toxic, evidence-based therapy for multiple myeloma patients and survivors.
…at least it is from my perspective as a long-term MMer and MM cancer coach. I believe that conventional chemotherapy regimens such as Velcade, Revlimid, Darzalex, etc. can kill MM. A two chemo regimen (doublet) kills more MM than a single regimen, a triple regimen kills more MM than a doublet, etc. etc.
Achieving remission after induction therapy, especially if you have minimal side effects is a great feeling. The two challenges for MMers are:
- collateral damage aka side effects from toxic therapies and
- MDR aka multi-drug resistance. Side effects can increase with the more chemo you have and the day will come when you relapse and conventional chemotherapy regimens no longer work.
The articles linked and excerpted below spell out how intravenous vitamin-C therapy kills or will weaken myeloma exposing your cancer to being killed by cytotoxic therapies or the evidence-based nutrition, supplementation and other therapies that show results in myeloma therapy.
If you or a loved one have been diagnosed with Multiple Myeloma, let me say this loud and clear:
It is critical that you become an active participant in your care. Learn everything you can.
I am alive today largely because I took the time to find out everything I could about Multiple Myeloma and sought out the full spectrum of evidence-based MM therapies both conventional (FDA approved) and non-conventional.
Your decision-making begins by learning about the full spectrum of evidence-based myeloma therapies, both conventional and non-conventional. To learn more about the Multiple Myeloma Coaching Course, click here.
Recommended Articles:
- Cannabidiol kills multiple myeloma and enhances Velcade against MM
- Antineoplaston Therapy (ANP)-From End Stage Multiple Myeloma to Complete Remission
- Multiple Myeloma Specialists- MM Cancer Coaching
Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid
“Multiple myeloma (MM) remains a difficult to cure disease in the majority of cases. Several preclinical and clinical studies have shown that ascorbic acid in pharmacologic doses (PAA) selectively kills cancer cells while sparing normal cells. This article reveals the biological mechanism by which PAA exerts its anti-cancer effects and should lead to the development of an innovative therapy in MM…”
Why high-dose vitamin C kills cancer cells
“Vitamin C breaks down to generate hydrogen peroxide, which can damage tissue and DNA. The new study shows that tumor cells with low levels of catalase enzyme activity are much less capable of removing hydrogen peroxide than normal cells, and are more susceptible to damage and death when they are exposed to high doses of vitamin C…
Most vitamin C therapies involve taking the substance orally. However, the UI scientists have shown that giving vitamin C intravenously — and bypassing normal gut metabolism and excretion pathways — creates blood levels that are 100 — 500 times higher than levels seen with oral ingestion. It is this super-high concentration in the blood that is crucial to vitamin C’s ability to attack cancer cells….”
Vitamin C in complementary oncology–update 2009.
“The antioxidant perhaps most widely used in complementary oncology is vitamin C, particularly by intravenous injection. In light of the recent clinical pharmacokinetic findings, the in vitro evidence of anti-tumor mechanisms and some well-documented cases of advanced cancers the role of high-dose intravenous vitamin C therapy in cancer treatment should be reassessed…”